The mutations of DNMT3A and/or NPM1, which are usually found in de novo AML and are mutually exclusive with ASXL1 and TP53 mutations, could identify patients for whom the definition of AML-MRC should be questioned. The gene discussed is ASXL1; the disease is acute myeloid leukemia.